Familial hypocalciuric hypercalcemia differential diagnosis: Difference between revisions
Usama Talib (talk | contribs) Created page with "__NOTOC__ {{Familial hypocalciuric hypercalcemia}} {{CMG}}; {{AE}} ==Overview== [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [c..." |
|||
Line 17: | Line 17: | ||
===Preferred Table=== | ===Preferred Table=== | ||
{| | {| class="wikitable" | ||
! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF||Differential diagnosis of Familial Hypocalciuric Hypercalcemia on the basis of hypercalcemia}} | |||
! colspan=" | |||
|- | |- | ||
! colspan="2" rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}} | |||
| | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}} | ||
! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | |||
! colspan="4" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}} | |||
| | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}} | ||
| | |||
| | |||
| | |||
|- | |- | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|PTH}} | |||
| | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Calcium}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Phosphate}} | |||
| | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Other findings}} | ||
| | |||
| | |||
|- | |- | ||
|style="background: # | | colspan="2" style="background: #F0FFFF; text-align: center;" |'''Familial hypocalciuric hypercalcemia''' | ||
|style="background: # | | style="background: #DCDCDC;" | | ||
* This is a genetic disorder caused my mutation in calcium-sensing receptor gene. | |||
|style="background: # | | style="background: #DCDCDC;" | | ||
* This is a benign condition and does not require treatment. | |||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |Normal/↑ | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |Normal/↑ | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" | | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" | -- | ||
|style="background: # | | style="background: #DCDCDC;" | | ||
* Calcium/creatinine clearance ratio | |||
|- | |- | ||
|style="background: # | | rowspan="3" style="background: #F0FFFF; text-align: center;" |'''Hyperparathyroidism''' | ||
|style="background: # | | style="background: #F0FFFF; text-align: center;" |Primary hyperparathyroidism | ||
|style="background: # | | style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a primary process in [[parathyroid gland]]. Parathyroid hormone causes increase in serum calcium. | ||
|style="background: # | | style="background: #DCDCDC;" | | ||
|style="background: # | * Usually asymptomatic | ||
|style="background: # | * Hypercalcemia detected on routine biochemical panel | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |↑ | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |↑ | ||
| | | style="background: #DCDCDC; text-align: center;" |↓/Normal | ||
| style="background: #DCDCDC; text-align: center;" |Normal/↑ calcitriol | |||
| rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption: | |||
* X-ray | |||
* DXA | |||
Preoperative localization of hyperfunctioning parathyroid gland: | |||
* Non-Invasive | |||
** Tc-99m sestamibi scintigraphy | |||
** Neck ultrasound | |||
** 4D-CT | |||
** SPET(P-SPECT) | |||
** PET | |||
** MRI | |||
* Invasive: | |||
** Super sensitive venous sampling | |||
** Selective arteriography | |||
** Angiography | |||
Predicting post-operative success: | |||
* Intraoperative parathyroid hormone monitoring | |||
|- | |- | ||
|style="background: #DCDCDC; | | style="background: #F0FFFF; text-align: center;" |Secondary hyperparathyroidism | ||
|style="background: # | | style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium. | ||
|style="background: # | | style="background: #DCDCDC;" | | ||
|style="background: # | * May present with history of: | ||
|style="background: # | ** Chronic renal failure | ||
|style="background: # | ** Vitamin D deficiency | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |↑ | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |↓/Normal | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" |↑ | ||
|style="background: # | | style="background: #DCDCDC; text-align: center;" | -- | ||
|style="background: # | |- | ||
|style="background: # | | style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism | ||
|style="background: # | | style="background: #DCDCDC;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. | ||
|style="background: # | | style="background: #DCDCDC;" | | ||
* Usually present with history of: | |||
** Kidney transplant | |||
* Usually hyperplasia of all four parathyroid glands | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
|- | |||
| rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref> | |||
| style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref> | |||
| style="background: #DCDCDC;" |Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. | |||
| style="background: #DCDCDC;" | | |||
* Most common cause of malignancy related hypercalcemia. | |||
* Usually present in solid tumors | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↓/Normal | |||
| style="background: #DCDCDC; text-align: center;" |↑ PTHrP | |||
Normal/↑ calcitriol | |||
| style="background: #DCDCDC;" | | |||
* Chest X-ray | |||
* CT scan | |||
* MRI | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |Osteolytic tumors | |||
| style="background: #DCDCDC;" |Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. | |||
| style="background: #DCDCDC;" | | |||
* Most commonly present in multiple myeloma and breast cancer. | |||
| style="background: #DCDCDC; text-align: center;" |↓ | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC;" | | |||
* DXA | |||
* X-ray | |||
* Mammography | |||
* Ultrasound | |||
* ESR | |||
* Serum protein electrophoresis | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |Production of calcitirol | |||
| style="background: #DCDCDC;" |Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. | |||
| style="background: #DCDCDC;" | | |||
* Most commonly present in lymphomas and in some ovarian germ cell tumors. | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ Calcitriol | |||
| style="background: #DCDCDC;" | | |||
* CT scan | |||
* MRI | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |Ectopic parathyroid hormone<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref> | |||
| style="background: #DCDCDC;" |Some tumors leads to ectopic production of parathyroid hormone. | |||
| style="background: #DCDCDC;" | | |||
* In rare instances, small cell carcinoma of lung may produce hypercalcemia by this process. | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↓/Normal | |||
| style="background: #DCDCDC; text-align: center;" |Normal/↑ Calcitriol | |||
| style="background: #DCDCDC;" | | |||
* Chest X-ray | |||
* CT scan | |||
* MRI | |||
|- | |||
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced''' | |||
| style="background: #F0FFFF; text-align: center;" |Lithium<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref> | |||
| style="background: #DCDCDC;" |Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. | |||
| style="background: #DCDCDC;" | | |||
* History of mood disorder | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC;" | | |||
* Lithium levels | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |Thiazide diuretics | |||
| style="background: #DCDCDC;" |Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia | |||
| style="background: #DCDCDC;" | | |||
* History of cardiac disorder | |||
* Rarely causes hypercalcemia | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC;" | -- | |||
|- | |||
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Nutritional''' | |||
| style="background: #F0FFFF; text-align: center;" |Milk-alkali syndrome | |||
| style="background: #DCDCDC;" |Hypercalcemia is be caused by high intake of calcium carbonate | |||
| style="background: #DCDCDC;" | | |||
* History of | |||
** High milk intake | |||
** Excess calcium intake for treating: | |||
*** Osteoporosis | |||
*** Dyspepsia | |||
* May lead to metabolic alkalosis and renal insufficiency. | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC;" | | |||
* Renal function test | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |Vitamin D toxicity | |||
| style="background: #DCDCDC;" |Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. | |||
| style="background: #DCDCDC;" | | |||
* History of: | |||
** Excess intake vitamin D | |||
** Excess milk fortified with vitamin D<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref> | |||
** Topical application of vitamin D analogue analogue calcipotriol<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref> | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ Vitamin D (calcidiol and/or calcitriol) | |||
| style="background: #DCDCDC;" | -- | |||
|- | |||
| style="background: #F0FFFF; text-align: center;" |'''Granulomatous disease''' | |||
| style="background: #F0FFFF; text-align: center;" |Sarcoidosis<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref> | |||
| style="background: #DCDCDC;" |Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. | |||
| style="background: #DCDCDC;" | | |||
* History of: | |||
** Cough | |||
** Dyspnea | |||
** Chest pain | |||
** Tiredness or weakness | |||
** Fever | |||
** Weight loss | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" |↑ | |||
| style="background: #DCDCDC; text-align: center;" | -- | |||
| style="background: #DCDCDC; text-align: center;" | | |||
* ↑ Calcitriol | |||
* ↑ ACE levels | |||
| style="background: #DCDCDC;" | | |||
* Chest X-ray | |||
* Biopsy | |||
|} | |} | ||
Revision as of 15:10, 21 September 2017
Familial hypocalciuric hypercalcemia Microchapters |
Differentiating Familial Hypocalciuric Hypercalcemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Familial hypocalciuric hypercalcemia differential diagnosis On the Web |
American Roentgen Ray Society Images of Familial hypocalciuric hypercalcemia differential diagnosis |
FDA on Familial hypocalciuric hypercalcemia differential diagnosis |
CDC on Familial hypocalciuric hypercalcemia differential diagnosis |
Familial hypocalciuric hypercalcemia differential diagnosis in the news |
Blogs on Familial hypocalciuric hypercalcemia differential diagnosis |
Risk calculators and risk factors for Familial hypocalciuric hypercalcemia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating X from other Diseases
- [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
- [Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
- As [disease name] manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Preferred Table
Differential diagnosis of Familial Hypocalciuric Hypercalcemia on the basis of hypercalcemia | ||||||||
---|---|---|---|---|---|---|---|---|
Disorder | Mechanism of hypercalcemia | Clinical features | Laboratory findings | Imaging & diagnostic modalities | ||||
PTH | Calcium | Phosphate | Other findings | |||||
Familial hypocalciuric hypercalcemia |
|
|
Normal/↑ | Normal/↑ | -- |
| ||
Hyperparathyroidism | Primary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a primary process in parathyroid gland. Parathyroid hormone causes increase in serum calcium. |
|
↑ | ↑ | ↓/Normal | Normal/↑ calcitriol | Findings of bone resorption:
Preoperative localization of hyperfunctioning parathyroid gland:
Predicting post-operative success:
|
Secondary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium. |
|
↑ | ↓/Normal | ↑ | -- | ||
Tertiary hyperparathyroidism | Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. |
|
↑ | ↑ | ↑ | -- | ||
Malignancy[1] | Humoral hypercalcemia of malignancy[2][3][4] | Tumor cells secretes parathyroid hormone related protein (PTHrP) which has similar action as parathyroid hormone. |
|
-- | ↑ | ↓/Normal | ↑ PTHrP
Normal/↑ calcitriol |
|
Osteolytic tumors | Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. |
|
↓ | ↑ | -- | -- |
| |
Production of calcitirol | Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. |
|
-- | ↑ | -- | ↑ Calcitriol |
| |
Ectopic parathyroid hormone[5] | Some tumors leads to ectopic production of parathyroid hormone. |
|
↑ | ↑ | ↓/Normal | Normal/↑ Calcitriol |
| |
Medication induced | Lithium[6] | Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy. |
|
↑ | ↑ | -- | -- |
|
Thiazide diuretics | Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia |
|
-- | ↑ | -- | -- | -- | |
Nutritional | Milk-alkali syndrome | Hypercalcemia is be caused by high intake of calcium carbonate |
|
-- | ↑ | -- | -- |
|
Vitamin D toxicity | Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. | -- | ↑ | -- | ↑ Vitamin D (calcidiol and/or calcitriol) | -- | ||
Granulomatous disease | Sarcoidosis[9] | Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. |
|
-- | ↑ | -- |
|
|
Use if the above table can not be made
Differential Diagnosis | Similar Features | Differentiating Features |
---|---|---|
Differential 1 |
|
|
Differential 2 |
|
|
Differential 3 |
|
|
Differential 4 |
|
|
Differential 5 |
|
|
References
- ↑ Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
- ↑ Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
- ↑ Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
- ↑ Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
- ↑ VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
- ↑ Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
- ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
- ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
- ↑ Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.